{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T09:34:27Z","timestamp":1760866467903,"version":"3.37.3"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Two new classifications of myeloid neoplasms have recently been published: the International Consensus Classification (ICC) and the 5th edition of the World Health Organization classification (WHO5). We sought to examine the real-world impact of dueling classifications on patient diagnoses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Our institutional pathology database was searched, and 237 specimens with a diagnosis of myeloid neoplasia were randomly selected. For each case, a classification based on the WHO5 and the ICC was assigned. The WHO5 and ICC diagnoses were compared to determine their degree of concordance.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>After applying the WHO5 and ICC diagnostic criteria, 134 (56.5%) cases were classified as concordant, 63 (26.6%) cases had terminological differences, 37 (15.6%) cases had minor diagnostic discrepancies, and 3 (1.3%) cases had major diagnostic discrepancies. Cases with minor diagnostic discrepancies included 25 cases of myelodysplastic syndrome (MDS), 10 cases of acute myeloid leukemia (AML), and 2 cases of myeloid precursor lesions. Cases with major diagnostic discrepancies included 2 cases that were diagnosed as MDS, not otherwise specified (NOS), according to the ICC but classified as AML with NPM1 alteration and AML with RBM15::MRTFA according to the WHO5 and 1 case that was characterized as chronic myelomonocytic leukemia according to the ICC and as AML with NPM1 alteration according to the WHO5.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study confirms that a majority of cases are classified similarly using the 2 systems. Given the overall similarity of the systems, future harmonization of the classifications should be pursued to avoid confusion and multiple diagnoses.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajcp\/aqad097","type":"journal-article","created":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T06:56:40Z","timestamp":1692255400000},"page":"566-570","source":"Crossref","is-referenced-by-count":7,"title":["Application of the International Consensus Classification and World Health Organization 5th edition classification to a series of myeloid neoplasms"],"prefix":"10.1093","volume":"160","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5872-0532","authenticated-orcid":false,"given":"Saurav","family":"Chopra","sequence":"first","affiliation":[{"name":"Department of Pathology, UPMC , Pittsburgh, PA , US"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6747-680X","authenticated-orcid":false,"given":"Nathanael G","family":"Bailey","sequence":"additional","affiliation":[{"name":"Department of Pathology, UPMC , Pittsburgh, PA , US"},{"name":"University of Pittsburgh , Pittsburgh PA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,8,17]]},"reference":[{"volume-title":"World Health Organization Classification of Tumours. Pathology & Genetics: Tumours of Haematopoietic and Lymphoid Tissues","year":"2001","author":"Jaffe","key":"2023120112205235400_CIT0001"},{"key":"2023120112205235400_CIT0002","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008","edition":"4"},{"key":"2023120112205235400_CIT0003","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2017","edition":"4"},{"key":"2023120112205235400_CIT0004","first-page":"1200","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume-title":"Blood.","author":"Arber","year":"2022"},{"year":"2022","author":"WHO Classification of Tumours Editorial Board","key":"2023120112205235400_CIT0005"},{"key":"2023120112205235400_CIT0006","first-page":"323","article-title":"Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal","volume-title":"Blood.","author":"Estey","year":"2022"},{"key":"2023120112205235400_CIT0007","first-page":"1703","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic\/dendritic neoplasms","volume-title":"Leukemia.","author":"Khoury","year":"2022"},{"key":"2023120112205235400_CIT0008","first-page":"2939","article-title":"Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes","volume-title":"Leukemia.","author":"Zeidan","year":"2022"},{"key":"2023120112205235400_CIT0009","first-page":"2160","article-title":"RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features","volume-title":"Leukemia.","author":"Gaidzik","year":"2016"},{"key":"2023120112205235400_CIT0010","first-page":"140","article-title":"Luspatercept in patients with lower-risk myelodysplastic syndromes","volume-title":"N Engl J Med.","author":"Fenaux","year":"2020"},{"key":"2023120112205235400_CIT0011","first-page":"69","article-title":"Advances in myelodysplastic\/myeloproliferative neoplasms","volume-title":"Virchows Arch.","author":"Prakash","year":"2023"},{"key":"2023120112205235400_CIT0012","first-page":"443","article-title":"Impact of the International Consensus Classification of myelodysplastic syndromes","volume-title":"Br J Haematol.","author":"Zhang","year":"2022"},{"key":"2023120112205235400_CIT0013","first-page":"922","article-title":"NPM1 mutations define a specific subgroup of MDS and MDS\/MPN patients with favorable outcomes with intensive chemotherapy","volume-title":"Blood Adv.","author":"Montalban-Bravo","year":"2019"}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/160\/6\/566\/53932558\/aqad097.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/160\/6\/566\/53932558\/aqad097.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T12:22:11Z","timestamp":1701433331000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/160\/6\/566\/7243495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,17]]},"references-count":13,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,8,17]]},"published-print":{"date-parts":[[2023,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ajcp\/aqad097","relation":{},"ISSN":["0002-9173","1943-7722"],"issn-type":[{"type":"print","value":"0002-9173"},{"type":"electronic","value":"1943-7722"}],"subject":[],"published-other":{"date-parts":[[2023,12,1]]},"published":{"date-parts":[[2023,8,17]]}}}